ArriVent BioPharma, Inc. Common Stock (AVBP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ArriVent BioPharma, Inc. Common Stock (AVBP) has a cash flow conversion efficiency ratio of -0.129x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-41.89 Million) by net assets ($323.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See AVBP cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
ArriVent BioPharma, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how ArriVent BioPharma, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ArriVent BioPharma, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ArriVent BioPharma, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cogeco Communications Inc
TO:CCA
|
0.046x |
|
Television Francaise 1 SA
PA:TFI
|
0.057x |
|
Shinkong Insurance Co Ltd
TW:2850
|
0.144x |
|
Max Stock Ltd
TA:MAXO
|
0.203x |
|
Ecovyst Inc
NYSE:ECVT
|
0.029x |
|
Zhejiang Sanwei Rubber Item Co
SHG:603033
|
0.002x |
|
Zhejiang Merit Interactive Network Technology Co Ltd Class A
SHE:300766
|
-0.009x |
|
Staidson Beijing Biopharma
SHE:300204
|
-0.049x |
Annual Cash Flow Conversion Efficiency for ArriVent BioPharma, Inc. Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of ArriVent BioPharma, Inc. Common Stock from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see AVBP stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $307.22 Million | $-160.59 Million | -0.523x | -91.82% |
| 2024-09-30 | $257.65 Million | $-70.21 Million | -0.273x | +26.17% |
| 2023-09-30 | $151.30 Million | $-55.84 Million | -0.369x | -47.58% |
| 2022-09-30 | $174.46 Million | $-43.63 Million | -0.250x | +18.10% |
| 2021-09-30 | $41.22 Million | $-12.59 Million | -0.305x | -- |
About ArriVent BioPharma, Inc. Common Stock
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutati… Read more